Announcements Trials

Browse Landscape

Phase

Phase 2/3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Lymphatic Abnormalities 1 Lymphangioma, Cystic 1 Lymphangioma 1

Interventions

Picibanil 1 Alpelisib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Lymphangioma × Alpelisib × Clear all

NCT05948943 2026-05-12

EPIK-L1

Novartis

Phase 2/3 Recruiting

Lymphangioma, Lymphangioma, Cystic, Lymphatic Abnormalities

Data powered by HemOnc (CC BY 4.0) Colophon ⚡